Published in Infect Immun on May 01, 2003
CrgA is an inducible LysR-type regulator of Neisseria meningitidis, acting both as a repressor and as an activator of gene transcription. J Bacteriol (2005) 1.08
Estimating costs associated with a community outbreak of meningococcal disease in a colombian Caribbean city. J Health Popul Nutr (2014) 0.87
Quantification of bacterial internalization by host cells using a beta-lactamase reporter strain: Neisseria gonorrhoeae invasion into cervical epithelial cells requires bacterial viability. Microbes Infect (2008) 0.84
Neisserial Heparin Binding Antigen (NHBA) Contributes to the Adhesion of Neisseria meningitidis to Human Epithelial Cells. PLoS One (2016) 0.75
Complete genome sequence of Neisseria meningitidis serogroup B strain MC58. Science (2000) 16.04
Complete DNA sequence of a serogroup A strain of Neisseria meningitidis Z2491. Nature (2000) 9.86
Roles of pilin and PilC in adhesion of Neisseria meningitidis to human epithelial and endothelial cells. Proc Natl Acad Sci U S A (1994) 2.06
Previously unrecognized vaccine candidates against group B meningococcus identified by DNA microarrays. Nat Biotechnol (2002) 1.83
Nucleotide sequence of the ksgA gene of Escherichia coli: comparison of methyltransferases effecting dimethylation of adenosine in ribosomal RNA. Gene (1985) 1.59
Down-regulation of pili and capsule of Neisseria meningitidis upon contact with epithelial cells is mediated by CrgA regulatory protein. Mol Microbiol (2002) 1.57
A mutation that enhances synthesis of sigma 32 and suppresses temperature-sensitive growth of the rpoH15 mutant of Escherichia coli. J Bacteriol (1990) 1.57
The general protein-export pathway is directly required for extracellular pullulanase secretion in Escherichia coli K12. Mol Microbiol (1991) 1.33
Pilus-mediated adhesion of Neisseria meningitidis: the essential role of cell contact-dependent transcriptional upregulation of the PilC1 protein. Mol Microbiol (1998) 1.32
Intimate adhesion of Neisseria meningitidis to human epithelial cells is under the control of the crgA gene, a novel LysR-type transcriptional regulator. EMBO J (2000) 1.30
The duality of virulence and transmissibility in Neisseria meningitidis. Trends Microbiol (2002) 1.28
Neisseria gonorrhoeae mutants altered in toxicity to human fallopian tubes and molecular characterization of the genetic locus involved. Infect Immun (1999) 0.88
Nod1 detects a unique muropeptide from gram-negative bacterial peptidoglycan. Science (2003) 7.49
Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infect Dis (2013) 2.95
Outbreak of W135 meningococcal disease in 2000: not emergence of a new W135 strain but clonal expansion within the electophoretic type-37 complex. J Infect Dis (2002) 2.88
Meningococcal meningitis: unprecedented incidence of serogroup X-related cases in 2006 in Niger. Clin Infect Dis (2007) 2.70
Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J Infect Dis (2009) 1.92
Clinical features and outcome of pediatric Neisseria meningitidis serogroup W135 infection: a report of 5 cases. Clin Infect Dis (2004) 1.69
The rise and fall of epidemic Neisseria meningitidis serogroup W135 meningitis in Burkina Faso, 2002-2005. Clin Infect Dis (2006) 1.66
From tailor-made to ready-to-wear meningococcal B vaccines: longitudinal study of a clonal meningococcal B outbreak. Lancet Infect Dis (2011) 1.58
Down-regulation of pili and capsule of Neisseria meningitidis upon contact with epithelial cells is mediated by CrgA regulatory protein. Mol Microbiol (2002) 1.57
Recent increase in meningitis Caused by Neisseria meningitidis serogroups A and W135, Yaoundé, Cameroon. Emerg Infect Dis (2002) 1.42
The role of particular strains of Neisseria meningitidis in meningococcal arthritis, pericarditis, and pneumonia. Clin Infect Dis (2003) 1.41
Continuing diversification of Neisseria meningitidis W135 as a primary cause of meningococcal disease after emergence of the serogroup in 2000. J Clin Microbiol (2004) 1.40
Transgenic mice expressing human transferrin as a model for meningococcal infection. Infect Immun (2007) 1.28
The duality of virulence and transmissibility in Neisseria meningitidis. Trends Microbiol (2002) 1.28
Epidemiological changes in meningococcal meningitis in Niger from 2008 to 2011 and the impact of vaccination. BMC Infect Dis (2013) 1.27
Correlations between carbon metabolism and virulence in bacteria. Contrib Microbiol (2009) 1.25
Correlation between alterations of the penicillin-binding protein 2 and modifications of the peptidoglycan structure in Neisseria meningitidis with reduced susceptibility to penicillin G. J Biol Chem (2003) 1.25
Molecular characterization of invasive meningococcal isolates from countries in the African meningitis belt before introduction of a serogroup A conjugate vaccine. PLoS One (2012) 1.23
Neisseria meningitidis strains isolated from invasive infections in France (1999-2002): phenotypes and antibiotic susceptibility patterns. Clin Infect Dis (2003) 1.23
The concept of "tailor-made", protein-based, outer membrane vesicle vaccines against meningococcal disease. Vaccine (2005) 1.17
A model of meningococcal bacteremia after respiratory superinfection in influenza A virus-infected mice. FEMS Microbiol Lett (2003) 1.17
Could the multicomponent meningococcal serogroup B vaccine (4CMenB) control Neisseria meningitidis capsular group X outbreaks in Africa? Vaccine (2012) 1.15
Detailed structural analysis of the peptidoglycan of the human pathogen Neisseria meningitidis. J Biol Chem (2003) 1.15
The Global Meningococcal Initiative: recommendations for reducing the global burden of meningococcal disease. Vaccine (2011) 1.14
Interlaboratory comparison of agar dilution and Etest methods for determining the MICs of antibiotics used in management of Neisseria meningitidis infections. Antimicrob Agents Chemother (2003) 1.10
Interlaboratory standardization of the sandwich enzyme-linked immunosorbent assay designed for MATS, a rapid, reproducible method for estimating the strain coverage of investigational vaccines. Clin Vaccine Immunol (2012) 1.06
A novel metal transporter mediating manganese export (MntX) regulates the Mn to Fe intracellular ratio and Neisseria meningitidis virulence. PLoS Pathog (2011) 1.04
Conserved virulence of C to B capsule switched Neisseria meningitidis clinical isolates belonging to ET-37/ST-11 clonal complex. Microbes Infect (2005) 1.03
The establishment of Neisseria meningitidis serogroup W135 of the clonal complex ET-37/ST-11 as an epidemic clone and the persistence of serogroup A isolates in Burkina Faso. Microbes Infect (2005) 1.02
Transcription regulators potentially controlled by HPr kinase/phosphorylase in Gram-negative bacteria. J Mol Microbiol Biotechnol (2003) 1.01
Meningococcal serogroup Y emergence in Europe: update 2011. Hum Vaccin Immunother (2012) 1.00
Influenza A virus neuraminidase enhances meningococcal adhesion to epithelial cells through interaction with sialic acid-containing meningococcal capsules. Infect Immun (2009) 0.99
Experimental meningococcal sepsis in congenic transgenic mice expressing human transferrin. PLoS One (2011) 0.98
Ciprofloxacin resistance in Neisseria meningitidis, France. Emerg Infect Dis (2008) 0.97
Standardized nonculture techniques recommended for European reference laboratories. FEMS Microbiol Rev (2006) 0.97
Differential modulation of TNF-alpha-induced apoptosis by Neisseria meningitidis. PLoS Pathog (2009) 0.96
Emergence of new virulent Neisseria meningitidis serogroup C sequence type 11 isolates in France. J Infect Dis (2010) 0.95
Molecular typing methods for outbreak detection and surveillance of invasive disease caused by Neisseria meningitidis, Haemophilus influenzae and Streptococcus pneumoniae, a review. Microbiology (2011) 0.93
Diversity of Greek meningococcal serogroup B isolates and estimated coverage of the 4CMenB meningococcal vaccine. BMC Microbiol (2014) 0.93
Impact of MenBvac, an outer membrane vesicle (OMV) vaccine, on the meningococcal carriage. Vaccine (2013) 0.91
Analysis in vitro and in vivo of the transcriptional regulator CrgA of Neisseria meningitidis upon contact with target cells. Mol Microbiol (2004) 0.89
Immunogenicity of meningococcal PBP2 during natural infection and protective activity of anti-PBP2 antibodies against meningococcal bacteraemia in mice. J Antimicrob Chemother (2006) 0.89
A multi-country evaluation of Neisseria meningitidis serogroup B factor H-binding proteins and implications for vaccine coverage in different age groups. Pediatr Infect Dis J (2013) 0.89
Association of meningococcal phenotypes and genotypes with clinical characteristics and mortality of meningitis in children. Pediatr Infect Dis J (2010) 0.88
Rifampin-resistant Neisseria meningitidis. Emerg Infect Dis (2006) 0.88
Lipocalin 2 in cerebrospinal fluid as a marker of acute bacterial meningitis. BMC Infect Dis (2014) 0.88
Meningococcal serogroup Y disease in Europe: Continuation of high importance in some European regions in 2013. Hum Vaccin Immunother (2015) 0.87
The Neisseria meningitidis adhesion regulatory protein CrgA acts through oligomerization and interaction with RNA polymerase. Mol Microbiol (2003) 0.87
Draft Genome Sequence of a Neisseria meningitidis Serogroup C Isolate of Sequence Type 11 Linked to an Outbreak among Men Who Have Sex with Men. Genome Announc (2013) 0.86
Mobile microbiological laboratory support for evaluation of a meningitis epidemic in Northern Benin. PLoS One (2013) 0.85
Use of available outer membrane vesicle vaccines to control serogroup B meningococcal outbreaks. Vaccine (2006) 0.85
Functional impacts of the diversity of the meningococcal factor H binding protein. Vaccine (2012) 0.85
The use of vaccine antigen characterization, for example by MATS, to guide the introduction of meningococcus B vaccines. Vaccine (2012) 0.85
Penicillin resistance compromises Nod1-dependent proinflammatory activity and virulence fitness of neisseria meningitidis. Cell Host Microbe (2013) 0.84
De-O-acetylation of peptidoglycan regulates glycan chain extension and affects in vivo survival of Neisseria meningitidis. Mol Microbiol (2013) 0.84
Increase of meningococcal serogroup Y cases in Europe: a reason for concern? Hum Vaccin Immunother (2012) 0.84
Enteroviral meningitis does not exclude concurrent bacterial meningitis. J Clin Microbiol (2011) 0.82
Differential role of lipooligosaccharide of Neisseria meningitidis in virulence and inflammatory response during respiratory infection in mice. Infect Immun (2006) 0.82
Evolution of immune response against Neisseria meningitidis B:14:P1.7,16 before and after the outer membrane vesicle vaccine MenBvac. Vaccine (2012) 0.81
Neisseria meningitidis pili induce type-IIA phospholipase A2 expression in alveolar macrophages. FEBS Lett (2005) 0.80
Target gene sequencing to define the susceptibility of Neisseria meningitidis to ciprofloxacin. Antimicrob Agents Chemother (2013) 0.80
Chronic meningococcemia cutaneous lesions involve meningococcal perivascular invasion through the remodeling of endothelial barriers. Clin Infect Dis (2012) 0.79
Whole-Genome Characterization of Epidemic Neisseria meningitidis Serogroup C and Resurgence of Serogroup W, Niger, 2015. Emerg Infect Dis (2016) 0.79
Penicillin binding proteins as danger signals: meningococcal penicillin binding protein 2 activates dendritic cells through Toll-like receptor 4. PLoS One (2011) 0.77
Immunisation against meningococcus B. Lancet (2013) 0.77
Laboratory evaluation of a rapid diagnostic test for Neisseria meningitidis serogroup A. Trans R Soc Trop Med Hyg (2013) 0.77
Transport and Catabolism of Carbohydrates by Neisseria meningitidis. J Mol Microbiol Biotechnol (2016) 0.77
Late repression of NF-κB activity by invasive but not non-invasive meningococcal isolates is required to display apoptosis of epithelial cells. PLoS Pathog (2011) 0.76
Neisseria meningitidis Serogroup X in Sub-Saharan Africa. Emerg Infect Dis (2016) 0.76
Invasive serogroup w meningococcal disease in children: a national survey from 2001 to 2008 in France. Pediatr Infect Dis J (2013) 0.76
Vaccine Failure After Meningococcal C Conjugate Vaccine May Be Linked to Decline of Bactericidal Titers and Absence of Herd Immunity. Pediatr Infect Dis J (2015) 0.75
Corticosteroids for bacterial meningitis. N Engl J Med (2008) 0.75
Travel-related Neisseria meningitidis serogroup W135 infection, France. Emerg Infect Dis (2013) 0.75
Neonatal Meningococcal Meningitis In France From 2001 To 2013. Pediatr Infect Dis J (2016) 0.75
[Meningococcal vaccines: present status and perspectives]. Therapie (2005) 0.75
Corticosteroid therapy in genotype ST-11 meningococcal infections. Pediatr Infect Dis J (2013) 0.75
Emerging drugs for acute bacterial meningitis. Expert Opin Emerg Drugs (2009) 0.75
Impact of changing epidemiology on vaccination strategies in Africa. Future Microbiol (2010) 0.75
Molecular typing of Neisseria perflava clinical isolates. APMIS (2012) 0.75
[Meningococcal disease due to Neisseria meningitidis serogroup W135 in children. Clinical aspects and outcome]. Presse Med (2004) 0.75
Proficiency of PCR in hospital settings for nonculture diagnosis of invasive meningococcal infections. Clin Lab (2012) 0.75